Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | mitochondrial RNA binding complex 1 subunit, putative | 0.0127 | 0.2969 | 0.5 |
Schistosoma mansoni | fusion | 0.0127 | 0.2969 | 0.2969 |
Echinococcus granulosus | ribosomal protein S6 kinase alpha 3 | 0.0205 | 0.5363 | 0.5363 |
Trypanosoma cruzi | WLM domain containing protein, putative | 0.0127 | 0.2969 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0356 | 1 | 1 |
Giardia lamblia | Kinase, AGC AKT | 0.0175 | 0.4469 | 0.5 |
Brugia malayi | Zn-finger in Ran binding protein and others containing protein | 0.0127 | 0.2969 | 0.2969 |
Loa Loa (eye worm) | hypothetical protein | 0.0127 | 0.2969 | 0.2969 |
Toxoplasma gondii | DNA topoisomerase domain-containing protein | 0.0356 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0127 | 0.2969 | 0.2969 |
Brugia malayi | Zn-finger in Ran binding protein and others containing protein | 0.0127 | 0.2969 | 0.2969 |
Schistosoma mansoni | hypothetical protein | 0.0127 | 0.2969 | 0.2969 |
Entamoeba histolytica | protein kinase, putative | 0.003 | 0 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0127 | 0.2969 | 0.5 |
Brugia malayi | SWIB/MDM2 domain containing protein | 0.0356 | 1 | 1 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0356 | 1 | 1 |
Toxoplasma gondii | Zn-finger in Ran binding protein and others domain-containing protein | 0.0127 | 0.2969 | 0.2969 |
Brugia malayi | brahma associated protein 60 kDa | 0.0356 | 1 | 1 |
Echinococcus granulosus | Upstream activation factor subunit UAF30 | 0.0356 | 1 | 1 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0356 | 1 | 1 |
Echinococcus multilocularis | SWI:SNF matrix associated | 0.0356 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0356 | 1 | 1 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others, putative | 0.0127 | 0.2969 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0205 | 0.5363 | 0.5363 |
Plasmodium vivax | hypothetical protein, conserved | 0.0356 | 1 | 0.5 |
Schistosoma mansoni | TRABID protein (C64 family) | 0.0127 | 0.2969 | 0.2969 |
Echinococcus multilocularis | ring and YY1 binding protein | 0.0127 | 0.2969 | 0.2969 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0036 | 0.0198 | 0.0198 |
Brugia malayi | Zn-finger in Ran binding protein and others containing protein | 0.0127 | 0.2969 | 0.2969 |
Schistosoma mansoni | brg-1 associated factor | 0.0356 | 1 | 1 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0127 | 0.2969 | 0.5 |
Loa Loa (eye worm) | AGC/RSK/RSK protein kinase | 0.0205 | 0.5363 | 0.5363 |
Toxoplasma gondii | SWIB/MDM2 domain-containing protein | 0.0356 | 1 | 1 |
Brugia malayi | ribosomal protein S6 kinase alpha 3 | 0.0175 | 0.4469 | 0.4469 |
Echinococcus granulosus | Zinc finger RanBP2 type | 0.0127 | 0.2969 | 0.2969 |
Entamoeba histolytica | protein kinase, putative | 0.003 | 0 | 0.5 |
Brugia malayi | Zn-finger in Ran binding protein and others containing protein | 0.0127 | 0.2969 | 0.2969 |
Loa Loa (eye worm) | hypothetical protein | 0.0127 | 0.2969 | 0.2969 |
Echinococcus granulosus | SWI:SNF matrix associated | 0.0356 | 1 | 1 |
Onchocerca volvulus | 0.0356 | 1 | 1 | |
Schistosoma mansoni | hypothetical protein | 0.0356 | 1 | 1 |
Schistosoma mansoni | RNA binding protein | 0.0127 | 0.2969 | 0.2969 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0127 | 0.2969 | 1 |
Chlamydia trachomatis | DNA topoisomerase I | 0.0356 | 1 | 0.5 |
Plasmodium vivax | SWIB/MDM2 domain-containing protein, putative | 0.0356 | 1 | 0.5 |
Brugia malayi | YY1-associated factor 2 | 0.0127 | 0.2969 | 0.2969 |
Loa Loa (eye worm) | brahma associated protein | 0.0356 | 1 | 1 |
Echinococcus granulosus | Nuclear pore complex protein Nup153 | 0.0127 | 0.2969 | 0.2969 |
Schistosoma mansoni | hypothetical protein | 0.0356 | 1 | 1 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0356 | 1 | 1 |
Echinococcus multilocularis | Nuclear pore complex protein Nup153 | 0.0127 | 0.2969 | 0.2969 |
Loa Loa (eye worm) | hypothetical protein | 0.0127 | 0.2969 | 0.2969 |
Loa Loa (eye worm) | SWIB/MDM2 domain-containing protein | 0.0356 | 1 | 1 |
Schistosoma mansoni | zinc finger protein | 0.0127 | 0.2969 | 0.2969 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0127 | 0.2969 | 0.5 |
Echinococcus multilocularis | Upstream activation factor subunit UAF30 | 0.0356 | 1 | 1 |
Plasmodium falciparum | SWIB/MDM2 domain-containing protein | 0.0356 | 1 | 1 |
Trypanosoma brucei | Zn-finger in Ran binding protein and others/FYVE zinc finger, putative | 0.0127 | 0.2969 | 1 |
Echinococcus granulosus | ring and YY1 binding protein | 0.0127 | 0.2969 | 0.2969 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others/FYVE zinc finger, putative | 0.0127 | 0.2969 | 0.5 |
Trypanosoma cruzi | Zn-finger in Ran binding protein and others, putative | 0.0127 | 0.2969 | 0.5 |
Echinococcus granulosus | zinc finger protein Ran binding | 0.0127 | 0.2969 | 0.2969 |
Echinococcus multilocularis | Zinc finger, RanBP2 type | 0.0127 | 0.2969 | 0.2969 |
Entamoeba histolytica | protein kinase, putative | 0.003 | 0 | 0.5 |
Echinococcus multilocularis | zinc finger protein Ran binding | 0.0127 | 0.2969 | 0.2969 |
Chlamydia trachomatis | SWIB complex protein | 0.0356 | 1 | 0.5 |
Echinococcus multilocularis | ribosomal protein S6 kinase alpha 3 | 0.0205 | 0.5363 | 0.5363 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0127 | 0.2969 | 1 |
Trypanosoma brucei | mitochondrial RNA binding complex 1 subunit | 0.0127 | 0.2969 | 1 |
Trypanosoma cruzi | mitochondrial RNA binding complex 1 subunit, putative | 0.0127 | 0.2969 | 0.5 |
Leishmania major | rac serine-threonine kinase, putative,protein kinase, putative | 0.0175 | 0.4469 | 1 |
Entamoeba histolytica | protein kinase, putative | 0.003 | 0 | 0.5 |
Toxoplasma gondii | ran binding protein | 0.0127 | 0.2969 | 0.2969 |
Trypanosoma cruzi | WLM domain containing protein, putative | 0.0127 | 0.2969 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0127 | 0.2969 | 0.2969 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.